Kohjin Bio Co., Ltd. Logo

Kohjin Bio Co., Ltd.

A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.

177A | T

Overview

Corporate Details

ISIN(s):
JP3283630006
LEI:
Country:
Japan
Address:
坂戸市千代田5−1−3
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kohjin Bio Co., Ltd. is a biotechnology company specializing in the development, manufacture, and sale of products for life sciences research and clinical applications. Its core offerings include tissue and cell culture media, media for microbial testing, and in-vitro diagnostic reagents. The company also provides animal-derived biological materials such as blood and serum. A key area of focus is regenerative medicine and cell therapy, where Kohjin Bio operates as a leading Contract Development and Manufacturing Organization (CDMO) in Japan, producing specialized culture media. Additionally, the company offers bioservices, including immunology contracts and the processing of cells for cancer immune therapies through partnerships with medical institutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:30
Report Publication Announcement
確認書
Japanese 8.9 KB
2025-11-13 07:30
Interim Report
半期報告書-第45期(2025/04/01-2026/03/31)
Japanese 215.4 KB
2025-06-27 08:30
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2025-06-24 09:09
Governance Information
内部統制報告書-第44期(2024/04/01-2025/03/31)
Japanese 25.0 KB
2025-06-24 09:08
Registration Form
確認書
Japanese 9.0 KB
2025-06-24 09:06
Annual Report
有価証券報告書-第44期(2024/04/01-2025/03/31)
Japanese 1.8 MB
2024-11-14 07:30
Regulatory News Service
確認書
Japanese 8.9 KB
2024-11-14 07:30
Interim Report
半期報告書-第44期(2024/04/01-2025/03/31)
Japanese 200.4 KB
2024-07-04 02:15
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2024-06-28 08:09
Registration Form
確認書
Japanese 9.0 KB
2024-06-28 08:00
Annual Report
有価証券報告書-第43期(2023/04/01-2024/03/31)
Japanese 1.7 MB
2024-04-25 05:44
Major Shareholding Notification
臨時報告書
Japanese 21.2 KB
2024-04-16 08:01
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-04-08 03:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-03-22 07:00
Registration Form
有価証券届出書(新規公開時)
Japanese 3.5 MB

Automate Your Workflow. Get a real-time feed of all Kohjin Bio Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kohjin Bio Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kohjin Bio Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Cartesian Therapeutics, Inc. Logo
Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.
United States of America
RNAC
CASI Pharmaceuticals, Inc. Logo
Develops and commercializes drugs for oncology, transplant, and autoimmune disease.
United States of America
CASI
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
United States of America
SAVA
CATALYST PHARMACEUTICALS, INC. Logo
Advancing therapies for rare neuromuscular and neurological diseases like LEMS.
United States of America
CPRX
cbdMD, Inc. Logo
Produces & distributes lab-tested CBD wellness products for people and pets.
United States of America
YCBD
CDT Equity Inc. Logo
Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.
United States of America
CDT
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom
CEL
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America
CELC
Celemics, Inc. Logo
Develops custom NGS panels and bioinformatics for research and clinical diagnostics.
South Korea
331920
Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.
South Korea
308430

Talk to a Data Expert

Have a question? We'll get back to you promptly.